Metrics as of 10/15/2026, 11:01 AM (Berlin time), refresh in progress.
KORU Medical Systems, Inc.
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably…
1D
+3.7%
1W
+4.4%
1M
-1.0%
6M
-26.8%
YTD
-46.5%
1Y
-24.9%
2Y
+13.9%
5Y
+8.4%
10Y
+623.3%
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~22% weaker price swings than usual
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 13/03/2026
P/E
-79.34
P/B
7.94
EV/EBITDA
-135.38
RETURN ON EQUITY
1.4%
NET MARGIN
2.1%
DEBT/EQUITY
0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
93.7%
FLOAT SHARES
43,049,664
AVG. DAILY VOLUME (30D)
260,219
French Donna
FLETCHER R JOHN
CASCELLA ROBERT
Manko Joseph M. Jr.
WHOLIHAN EDWARD
KORU Medical Systems, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Adam Kalbermatten, the company employs around 73 people.
The IPO was on 05/04/1994; the stock trades on NASDAQ under the ticker KRMD.
5 analysts rate the stock, the consensus is Buy (as of 13/03/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
No, KORU Medical Systems currently does not pay a dividend.
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
Clicking "Analyze stock" lets five strategies assess KORU Medical Systems against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.